NCI Featured Clinical Trials

Potentially Less Toxic Adjuvant Chemotherapy for Women with Breast Cancer

2013-04-11 00:00:00.0

In this phase III trial, women with resected HER2-negative breast cancer that has either spread to nearby lymph nodes or has characteristics associated with a high risk of recurrence will be randomly assigned to receive one of four anthracycline-based chemotherapy regimens or six courses of docetaxel and cyclophosphamide.

New Combination Therapy for Untreated Multiple Myeloma

2013-02-26 00:00:00.0

In this phase II trial, people with newly diagnosed multiple myeloma will be treated with carfilzomib, lenalidomide, and dexamethasone for eight 28-day treatment cycles.

Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer

2013-02-05 00:00:00.0

In this phase III trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomly assigned either to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy without chemotherapy.

Experimental Drug for Relapsed or Resistant Ovarian Cancer

2013-01-08 00:00:00.0

In this trial, women with metastatic or unresectable epithelial ovarian, fallopian tube, or primary peritoneal cancer that has recurred after, or has not responded to, previous therapies will receive the experimental drug birinapant.

Treating Patients with High-Risk Smoldering Myeloma

2012-12-11 00:00:00.0

In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide.

Dietary Intervention for Patients Receiving Chemoradiotherapy for Lung Cancer

2012-11-13 00:00:00.0

In this phase I clinical trial, patients with advanced non-small cell lung cancer who are about to undergo chemoradiation therapy will consume a very low-carbohydrate ketogenic diet for the duration of their treatment.

Comparing Relaxation Programs for Breast Cancer Patients Receiving Radiotherapy

2012-10-16 00:00:00.0

In this study, women with breast cancer who have had surgery and are scheduled to undergo radiation therapy will be randomly assigned to one of two different stretching and relaxation programs or to a control group that will receive usual care.

Comparing Radiation Therapy Regimens for Early-Stage Breast Cancer

2012-10-02 00:00:00.0

In this phase III clinical trial, women with early-stage breast cancer will be randomly assigned to undergo a standard 5-week course of whole-breast irradiation (WBI) followed by a sequential boost course or 3 weeks of hypofractionated WBI with a concurrent boost.

Treating KSHV-Associated Multicentric Castleman Disease

2012-09-18 00:00:00.0

In this pilot study, patients with KSHV-associated multicentric Castleman disease will receive intravenous tocilizumab every other week for up to 12 weeks. Patients who do not benefit from tocilizumab therapy alone may go on to receive high-dose AZT and valganciclovir in addition to tocilizumab.

Targeting Invasive Glioma Cells

2012-09-04 00:00:00.0

In this trial, patients with glioblastoma that has not responded to standard postoperative therapy or that has progressed will be treated with varying amounts of a Trk inhibitor called AZD7451 to determine the maximum tolerated dose and the side effects of this drug.